I’m a financial editor with a proven track record of identifying stocks that significantly outperform the market. My investment advice can be found in Forbes Investor and Forbes Special Situation Survey – the two longest running investment newsletters currently published by Forbes Media LLC – for which I serve as editor.

Having joined Forbes in January 2000 as an equity analyst, I’ve gained over a decade of experience analyzing equities across multiple sectors and industries. I also served as the associate editor of the Forbes Investor from June 2004 to July 2010. I earned a B.S. in Marketing and International Business from the Stern School of Business at New York University and hold the Chartered Financial Analyst designation. My stock selections from the Forbes Investor have been featured on Forbes.com, Yahoo Finance, MSN Money, Seeking Alpha, the Money Show and the Dick Davis Digest.
*As of 12/31/2016.

loading...

7/27/2017 @ 4:29PM

Supplementary Review: Gilead Sciences (GILD), July 27, 2017

Q2 revenues fell 8.2% year-over-year to $7.14 billion. This was driven by a 9.6% decrease in Antiviral product sales to $6.44 billion as ongoing strong uptake of its new HIV regimens was more than offset by a continued decline in sales of its hepatitis C (HCV) treatments, which fell [...]